[Edaily Reporter Kim Jinsoo ] On the 14th, in the pharmaceutical and biotech sector, INFINITT Healthcare(071200)shares soared to the daily price limit following news that the company would pay a cash dividend totaling 65.4 billion won. #SAMIK PHARM. Co., LTD.’s stock rose nearly 20% after the company announced it had obtained a patent for a long-acting injectable drug. JETEMA Co.,Ltd.(216080)shares rose, driven by expectations of improved earnings resulting from toxin exports to Thailand.
INFINITT Healthcare stock price trend. (Photo: KG Zeroin MP Doctor)
Why INFINITT Healthcare’s Stock Price Soared to the Daily Limit
According to KG Zeroin MP Doctor (MP DOCTOR, formerly Market Point), INFINITT Healthcare’s stock shot straight to the daily upper limit right from the market open that day. As a result, the stock price soared to 11,310 won. The rise in INFINITT Healthcare’s stock price is attributed to news of a 65 billion won dividend.
On the 11th, after the market closed, INFINITT Healthcare announced a plan to pay cash dividends totaling 65.4 billion won for the 2026–2027 period to enhance shareholder value. The company plans to pay a total of 2,681 won per share, consisting of 820 won in the third quarter of 2026, a year-end dividend of 1,230 won for the 2026 fiscal year, and 631 won in the second quarter of 2027.
INFINITT Healthcare is a medical information technology (IT) company that develops and supplies medical imaging solutions. It develops and supplies hospitals with Picture Archiving and Communication Systems (PACS) for storing, managing, and transmitting medical images, as well as 3D medical imaging software.
INFINITT Healthcare’s dividend of approximately 65 billion won is based on accumulated retained earnings and financial assets. It is believed that INFINITT Healthcare’s decision to pay dividends was influenced by demands from minority shareholders, which have continued since last year, for improvements to corporate governance and greater shareholder returns.
The conflict between INFINITT Healthcare and its minority shareholders intensified when the minority shareholders raised concerns that, despite a prolonged absence of dividends, the company had been paying management consulting fees to SOLBORN, Inc., the largest shareholder, and maintaining a family-controlled corporate governance structure. Last year, minority shareholders attempted to dismiss the existing auditor and appoint a new one, but the matter escalated into a legal dispute after INFINITT Healthcare passed an amendment to the articles of incorporation that strengthened the eligibility requirements for auditors.
INFINITT Healthcare, which had maintained a policy of no dividends, introduced quarterly dividends in 2025 as the conflict with minority shareholders intensified and decided to return the full amount of its legally distributable funds—approximately 65.4 billion won—to shareholders.
An INFINITT Healthcare official stated, “This dividend does not involve any special allocation of funds; rather, we are proceeding with quarterly dividends by utilizing distributable funds available under the Commercial Act.”
stock price closed at 9,430 won, up 19.60% from the previous day. The rise in SAMIK PHARM. Co., LTD.’s stock price is attributed to expectations surrounding its long-acting injectable technology.
On the 14th, SAMIK PHARM. Co., LTD. announced that on the 27th of last month, it had completed the registration of a domestic patent for a long-acting microparticle technology capable of slowly releasing the immunomodulatory peptide thymosin alpha-1 in the body for up to four weeks. This patent covers formulation technology designed to reduce the burden of repeated administration for thymosin alpha-1, which requires frequent dosing.
Thymosin alpha-1 is a peptide that regulates immune function; however, it requires repeated administration to maintain its therapeutic effect, which can be inconvenient. To alleviate this inconvenience, SAMIK PHARM. Co., LTD. developed a method of encapsulating the drug within extremely small, biodegradable polymer particles. These particles gradually degrade within the body over a set period. During this process, the cyclosporine alpha-1 contained within is also released in small amounts. The formulation is designed so that the drug is released continuously over a period of up to four weeks, rather than all at once.
SAMIK PHARM. Co., LTD. stated, “Based on this patented technology, we will be able to reduce the frequency of injections compared to current treatments and, ultimately, pursue the development of a long-acting cymosin alpha-1 injection that requires only once-monthly administration.”
However, a cautious approach is necessary, as opinions are divided on whether SAMIK PHARM. Co., LTD.’s long-acting injectable technology actually possesses commercial competitiveness. Furthermore, this patent does not immediately imply the commercialization of a once-monthly product; additional research and regulatory approval procedures are required to develop it into an actual pharmaceutical product.
Some analysts suggest that the rise in SAMIK PHARM. Co., LTD.’s stock price is due not only to the patent acquisition but also to spillover benefits from news related to Peptron, Inc., another domestic long-acting injectable drug company. On the 11th, Peptron, Inc. stated on its website, “October 7 marks the date related to the basic term of the joint research agreement with Eli Lilly; it does not signify the deadline for signing a follow-up commercial agreement.”
Through a platform technology evaluation agreement signed on October 7, 2024, Peptron, Inc. and Lilly agreed to assess whether Peptron, Inc.’s SmartDepot technology could be applied to Lilly’s peptide drugs, and Peptron, Inc. granted Lilly a non-exclusive license. In a corrected disclosure last December, Peptron, Inc. added the condition of “up to 24 months” to the contract period, which had originally been stated as “approximately 14 months,” and the market had expected a decision on whether to sign the contract by October 7 of this year.
However, following Peptron, Inc.’s explanation on the 11th, uncertainty regarding whether the contract would be signed increased, causing Peptron, Inc.’s stock price to fall 5.27% to 138,300 won that day.
JETEMA Co.,Ltd.: Expectations for Full-Scale Results in the Thai Market
JETEMA Co.,Ltd.’s stock price rose 6.91% from the previous day to 7,120 won. This is interpreted as reflecting expectations that JETEMA Co.,Ltd.’s entry into
the Thai market
will begin to yield
substantial results
.
JETEMA Co.,Ltd. is accelerating its push into the Thai market after securing product approval for its botulinum toxin “Zetema Dertoxin 100U” from the Thai Food and Drug Administration (TFDA) in June of this year. This approval marks JETEMA Co.,Ltd.’s first overseas product approval for a botulinum toxin product.
Previously, JETEMA Co.,Ltd. signed a five-year toxin supply contract with a Thai partner in 2024 worth approximately $32 million (about 44 billion won), and based on this approval, the company has decided to expand product supply and sales through its local partner, Aestema. JETEMA Co.,Ltd. plans to leverage the medical aesthetics sales network established by Aestema in Thailand, as well as its existing marketing system built on filler sales.
The Thai botulinum toxin market is expected to experience significant growth in the future. According to market research firm Grand View Research, the Thai botulinum toxin pharmaceutical market is projected to expand from approximately $69 million (about 92.8 billion won) in 2025 to approximately $74.1 million (about 99.7 billion won) in 2026. Subsequently, the market is expected to grow at an average annual rate of 10% from this year through 2040, reaching a market size of $282.5 million (approximately 380 billion won) by 2040.
A JETEMA Co.,Ltd. official stated, “It appears the stock price has risen as expectations for exports of botulinum toxin to Thailand and strong performance have been reflected,” adding, “Expectations seem to be rising as the company has recently made frequent mentions on video-based platforms regarding its expansion into Thailand.”
The revised wage and collective bargaining agreement (CBA) proposal, drafted by SK hynix management and labor following the rejection of the previous tentative agreement, was approved in a re-vote by …
HAZZYS, a premium contemporary casual brand operated by LF(093050), is expanding into Hong Kong. Following its entry into mainland China, the brand aims to establish itself as a premium brand in the G…
LG Uplus(032640)has renovated “U+ The Gap Between the Ordinary and the Extraordinary,” a multi-purpose cultural space near Gangnam Station in Seoul, into a customer-participatory art platform.Located …
